GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » EV-to-EBITDA

Burning Rock Biotech (Burning Rock Biotech) EV-to-EBITDA : -0.03 (As of Apr. 28, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Burning Rock Biotech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Burning Rock Biotech's enterprise value is $2.71 Mil. Burning Rock Biotech's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-100.33 Mil. Therefore, Burning Rock Biotech's EV-to-EBITDA for today is -0.03.

The historical rank and industry rank for Burning Rock Biotech's EV-to-EBITDA or its related term are showing as below:

BNR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -99.99   Med: -1.65   Max: 0.15
Current: -0.03

During the past 6 years, the highest EV-to-EBITDA of Burning Rock Biotech was 0.15. The lowest was -99.99. And the median was -1.65.

BNR's EV-to-EBITDA is ranked worse than
100% of 118 companies
in the Medical Diagnostics & Research industry
Industry Median: 15.85 vs BNR: -0.03

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-28), Burning Rock Biotech's stock price is $0.85. Burning Rock Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.979. Therefore, Burning Rock Biotech's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Burning Rock Biotech EV-to-EBITDA Historical Data

The historical data trend for Burning Rock Biotech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burning Rock Biotech EV-to-EBITDA Chart

Burning Rock Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial - - -36.39 -6.66 -0.88

Burning Rock Biotech Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.76 -0.88 -1.38 -1.12 -0.15

Competitive Comparison of Burning Rock Biotech's EV-to-EBITDA

For the Diagnostics & Research subindustry, Burning Rock Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Burning Rock Biotech's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Burning Rock Biotech's EV-to-EBITDA falls into.



Burning Rock Biotech EV-to-EBITDA Calculation

Burning Rock Biotech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2.705/-100.33
=-0.03

Burning Rock Biotech's current Enterprise Value is $2.71 Mil.
Burning Rock Biotech's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-100.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Burning Rock Biotech  (NAS:BNR) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Burning Rock Biotech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.85/-0.979
=At Loss

Burning Rock Biotech's share price for today is $0.85.
Burning Rock Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.979.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Burning Rock Biotech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Burning Rock Biotech (Burning Rock Biotech) Business Description

Traded in Other Exchanges
Address
No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples.

Burning Rock Biotech (Burning Rock Biotech) Headlines

From GuruFocus

Burning Rock Publishes 2022 Annual Report on Form 20-F

By GlobeNewswire GlobeNewswire 04-21-2023

Burning Rock Announces Resignation of Director

By GlobeNewswire GlobeNewswire 07-15-2022

Admission to Trading on the London Stock Exchange

By Value_Insider Value_Insider 11-01-2022

Burning Rock Announces Changes to Board Composition

By PurpleRose PurpleRose 07-14-2022

Burning Rock provides an update on 2022 revenue guidance

By Stock market mentor Stock market mentor 01-18-2023

Burning Rock provides an update on 2022 revenue guidance

By GlobeNewswire GlobeNewswire 01-18-2023